HALIFAX, Nova Scotia –January 4, 2015 — Athletigen Technologies Inc., a sports genetics company, today announced it has raised US$1.55M in seed funding to propel the growth of the Athletigen Performance Platform – a tool used by elite athletes, including professionals and Rio 2016 Olympians, and their coaches. The financing was led by Exponential Partners, a venture capital fund specializing in the application of breakthrough technologies in consumer health and human performance.
Athletigen uses an innovative interface to present sports genetics analysis in a format that athletes and coaches, looking to improve performance, can easily understand and incorporate into their training plan. Athletigen has been working extensively with Olympic coaches and athletes and have also recently partnered with Affymetrix (a global leader in genotyping microarray technology) to enhance its expert informed proprietary DNA analysis, which analyzes 850,000 genetic variants that will inform human athletic performance research.
Taking advantage of a fast growing consumer genomics market, Athletigen will be using the funds to advance its human performance platform to help athletes unlock their potential. Through genetic analysis, athletes will gain a deeper and immediately applicable understanding of how their genetics influence athletic performance.
Jeremy Koenig, Ph.D., CEO of Athletigen said, “We are proud of what our outstanding team has accomplished to date, launching the world’s most comprehensive sports genetics analysis platform. We welcome the confidence and guidance of Exponential Partners and our other investors and look forward to using these new resources to establish Athletigen as the leading human performance brand in the field of genomics.”
In conjunction with the financing, Exponential Partners’, Pat Wilkison will join Athletigen’s Board of Directors.
Pat Wilkison, general partner at Exponential Partners noted, “Athletigen is leading the charge of a genomic revolution, making this an exciting investment opportunity. Their unique ability to analyze individual athletic traits and recommend effective action holds tremendous potential, particularly as advances in technology have made genetic testing so affordable. With a staff consisting of high performance athletes and the top scientific minds in applied genomics, their knowledge of both athletics and science makes them unrivalled in the industry. We are infinitely committed to providing the support needed to help to fuel the adoption of Athletigen by the world’s athletes.”
Exponential Partners joins existing strategic investors Dr. Ray Muzyka (Medical Doctor, Co-founder of Bioware and CEO of Threshold Impact, an angel investor fund supporting disruptive innovations in information technology, new media and medical innovation with capable, passionate entrepreneurs) and Content Bloom (a digital agency that helps companies approach, implement and evolve technology solutions).
About Exponential Partners
Exponential Partners is a unique blend of a venture capital fund, an accelerator, and an operating advisor. Adding the real world experience of dozens of CEOs who are investors in the fund, Exponential Partners provides meaningful value beyond capital to early stage companies. Through its extensive global network, the firm helps entrepreneurs gain visibility and build strategic relationships. Exponential Partners is currently investing its new $155 million fund in high-growth, disruptive technologies in the consumer health and human performance sectors. Visit Exponential Partners at www.exponential.vc.
Athletigen Technologies Inc. is transforming the future for how athletes train. The Company’s interpretive bioinformatics algorithm provides a sports-based DNA analysis to consumers. Athletigen’s easy-to-use, actionable dashboard identifies how a person’s genetics specifically affects their athleticism, nutrition and sports psychology, and creates a personalized blueprint for precision performance. Athletigen’s platform is built on an extensive database of genetic indicators that has been built over nearly two-decades of sports genetics research. To learn more visit www.athletigen.com.